We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and Safety of Tinzaparin Thromboprophylaxis in Lung Cancer Patients with High Thromboembolic Risk: A Prospective, Observational, Single-Center Cohort Study.
- Authors
Kouvela, Marousa; Livanou, Maria Effrosyni; Stefanou, Dimitra T.; Vathiotis, Ioannis A.; Sarropoulou, Fotini; Grammoustianou, Maria; Dimakakos, Evangelos; Syrigos, Nikolaos
- Abstract
Simple Summary: Cancer is implicated in multiple pathways that increase thrombogenicity, and lung cancer patients have a 20% higher risk of venous thromboembolism in comparison to the general population. Venous thromboembolic disease (VTE) in cancer patients, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), can lead to the delay of cancer treatment and, thus, result in increased mortality, morbidity, and burden on healthcare resources. Factors contributing to thrombotic burden are related to cancer, patients, treatment, and laboratory findings. Thromboprophylaxis during active lung cancer treatment with adequate anticoagulation might improve outcomes. Thromboprophylaxis with low molecular weight heparin (LMWH) is the standard of care, but due to the vast heterogeneity of lung cancer patients, there is no consensus on the optimal dose and duration of the treatment. Background: The aim of this study was to record and assess the efficacy and safety ofthromboprophylaxis with an intermediate dose of Tinzaparin in lung cancer patients with high thrombotic risk. Methods: This was a non-interventional, single-arm, prospective cohort study of lung cancer patients who received thromboprophylaxis with Tinzaparin 10.000 Anti-Xa IU in 0.5 mL, OD, used in current clinical practice. Enrolled ambulatory patients signed informed consent. Anti-Xa levels were tested. Results: In total, 140 patients were included in the study, of which 81.4% were males. The histology of the tumor was mainly adenocarcinoma. Lung cancer patients with high thrombotic risk based on tumor, patient, treatment, and laboratory-related factors were enrolled. Only one patient experienced a thrombotic event (0.7%), and 10 patients had bleeding events (7.1%), including only one major event. Anti-Xa levels measured at 10 days and 3 months did not differ significantly between patients who developed hemorrhagic events and those who did not (p = 0.26 and p = 0.32, respectively). Conclusion: Thromboprophylaxis with an intermediate Tinzaparin dose in high thrombotic-risk lung cancer patients is a safe and effective choice for the prevention of VTE.
- Subjects
THROMBOEMBOLISM risk factors; RISK assessment; PULMONARY embolism; ANTICOAGULANTS; ADENOCARCINOMA; PATIENT safety; LOW-molecular-weight heparin; VEINS; VENOUS thrombosis; SCIENTIFIC observation; FIBRINOLYTIC agents; CANCER patients; TREATMENT effectiveness; TREATMENT duration; DESCRIPTIVE statistics; ENOXAPARIN; LONGITUDINAL method; LUNG tumors; CONFIDENCE intervals; PHARMACODYNAMICS
- Publication
Cancers, 2024, Vol 16, Issue 7, p1442
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers16071442